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Abstract 
 
Background: The prognostic role of preoperative serum lipid levels in patients undergoing 
radical prostatectomy (RP) for clinically localized prostate cancer (PCa) is unclear. The aim 
of the present study was to investigate preoperative serum lipid levels in patients with 
clinically localized PCa undergoing RP and their association with clinicopathological features 
and oncological outcome. 
Methods: Preoperative lipid levels (total cholesterol, LDL cholesterol, HDL cholesterol and 
triglycerides) and statin use from consecutive patients with clinically localized PCa 
undergoing RP in a tertiary referral center between 2008 and 2015 were recorded and patients 
were followed prospectively. Logistic regression analysis was used to test the association 
between lipid levels and clinicopathological parameters. Lipid values were analyzed both as 
continuous and dichotomized variables. Univariable and multivariable Cox regression 
analyses were performed to identify predictors for recurrence-free survival (RFS). Recurrence 
was defined as rising and verified PSA levels >0.1 ng/mL. 
Results: Our cohort consisted of 371 men with a median age of 63 years (range 41-78 years) 
and a median preoperative PSA value of 6.79 ng/mL (0.43–81.4 ng/mL). Median follow-up 
was 28 months (1-64). No association was found between lipid levels and adverse 
pathological characteristics such as ≥pT3, Gleason score ≥8, positive nodal status and positive 
surgical margins. Recurrence occurred in 49 patients (15.4%) at a median time of 18 months 
(2-51 month). Compared to low LDL cholesterol, high LDL cholesterol was associated with 
longer RFS in univariable analysis (continuous: Hazard Ratio (HR): 0.67, 95%-Confidence 
Interval (CI): 0.47-0.96, p=0.03; 3 mM cut-point: HR: 0.44, 95%-CI: 0.24-0.79, p=0.006). 
Neither levels of other lipids, nor statin use were associated with RFS. Preoperative LDL 
cholesterol remained an independent predictor for PCa recurrence in a multivariable model 
adjusted for age, preoperative PSA, statin use, tumor stage, Gleason score, nodal status and 
surgical margin status (continuous: HR: 0.66, 95%-CI: 0.44-0.99, p=0.04; 3 mM cut-point: 
HR: 0.41, 95%-CI: 0.21-0.78, p=0.007). 
Conclusions: This is the first prospective study showing the potential adverse and 
independent prognostic role of low preoperative LDL cholesterol levels in patients with 
localized PCa undergoing RP. 
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Introduction 
Prostate cancer (PCa) is one of the most commonly diagnosed cancers among men 
worldwide, with an estimated 1.1 million new cases and 0.3 million PCa-related deaths per 
year [1]. One well established treatment option for localized PCa with good long-term cancer 
control is radical prostatectomy (RP) [2]. Biochemical recurrence (BCR) after RP is often 
assumed to represent cancer and precede clinical progression. Even in specialized high-
volume centers BCR rates after RP might reach up to 40% after 10 years [3]. 
The impact of serum lipid levels on the incidence of PCa and its natural course remains 
controversial [4,5]. A recent meta-analysis showed that total cholesterol, high-density 
lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol serum levels are 
unlikely to be associated with PCa risk [6]. However, the role of dyslipidemia in secondary 
prevention as a potential modifiable risk factor for PCa recurrence is even less clear. The 
association between complete preoperative serum lipid status and biochemical recurrence 
(BCR) after curative treatment for clinically localized PCa has only been investigated in a few 
studies, which have reported conflicting results [7–10]. For example, one study reported 
elevated serum triglycerides to be associated with increased risk of PCa recurrence [7], 
whereas another study found an association between hypertriglyceridemia and longer BCR-
free survival [8]. Based on the conflicting results of studies in PCa patients, the association of 
preoperative lipid levels with BCR after curative treatment for localized PCa warrants further 
analysis. The aim of this study was to examine the association between the complete 
preoperative lipid status, clinicopathological features and BCR in men with clinically 
localized PCa. 
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Materials and Methods 
Study design 
Men with clinically localized PCa undergoing laparoscopic robotic assisted RP were 
prospectively included in this single-center cohort study (Prostate Cancer outcomes cohort 
study: ProCOC [11]). The study was approved by the Ethics Committee of Canton Zürich 
(protocol name: ProCOC: The Prostate Cancer Outcomes Cohort Study, protocol number: 
Ref. Nr. StV KEK-ZH-Nr. 06/08). The cohort consisted only of men with clinically localized 
PCa who were scheduled for RP at our tertiary referral center and gave informed consent. 
Patients were normally followed on a regular basis for every three months the first year and 
afterwards at least annually or on an individual basis depending on the disease course. A PSA 
value of 0.1 ng/ml or higher was defined as BCR. Patients were censored if lost to follow-up 
or event-free at their most recent clinic visit. Patients with a postoperative PSA persistence or 
without distinct follow-up data for the endpoint BCR were excluded from the analysis of 
BCR. 
 
Pathologic analysis 
All surgical specimens were processed according to standard histopathological procedures. At 
least one uropathologist assigned pathologic stage, tumor grade and node status. Surgical 
margins were considered positive if any neoplastic cells were in contact with the inked 
surface of the prostatectomy specimen. Tumor characteristics were obtained from pathology 
reports according to the WHO/ISUP 2016 classification. 
 
Analysis of serum lipids 
Preoperative serum lipid levels (total cholesterol, LDL cholesterol, HDL cholesterol and 
triglycerides) were assessed the day before surgery for all men according to the study 
protocol. Additionally, statin use at the time of surgery was recorded. The duration of 
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preoperative statin intake was not taken into account in this study. Blood analysis was 
performed by the hospital’s Institute of Clinical Chemistry. Total cholesterol, HDL 
cholesterol and triglycerides were determined by enzymatic colorimetric tests in a modular 
analyzer (Cobas 8000, Roche Diagnostics GmbH, Mannheim, D). Friedewald´s formula ( 
LDL cholesterol = Total cholesterol – [ HDL cholesterol + { triglycerides / 5 } ] ) was used to 
calculate serum LDL cholesterol values [12]. However, this formula is not valid for 
triglyceride levels >4.5 mmol/L (mM) and patients with levels above this threshold were thus 
excluded from any analysis using LDL cholesterol as a variable. 
 
Statistical analysis 
Univariable logistic regression analysis was used to analyse the association between serum 
lipid levels, statin use and clinicopathological tumor characteristics. Clinicopathological study 
outcomes were extraprostatic disease (≥pT3), high-risk disease (Gleason Score ≥8), positive 
nodal status (pN1) and positive surgical margins (PSM). 
Serum lipid levels in the regression analysis were analyzed as continuous and as binary 
variables. Cut-points were selected according to the reference values of the hospital’s Institute 
of Clinical Chemistry that are based on internationally accepted threshold values (total 
cholesterol: 5 mM, LDL cholesterol: 3 mM, HDL cholesterol: 1 mM, triglycerides: 1.7 mM) 
[13]. 
Univariable and multivariable Cox regression models addressed the association of serum lipid 
levels with BCR after RP. Adjustments were made for age, preoperative PSA, statin use, 
tumor stage, Gleason score, nodal status and surgical margin status. We constructed Cox 
regression models for each single adjustment factor and one model containing all adjustment 
factors. 
Cut-point analysis was conducted for independently prognostic serum lipid values to detect 
other significant dichotomization cut-points (0.5 mM increments). Multiple comparisons were 
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handled by adjusting the p-values with the false-discovery rate (FDR) approach described by 
Benjamini & Hochberg [14]. Finally, Kaplan-Meier survival plots with their corresponding 
log-rank tests were drawn for all significant cut-points that were found in the cut-point 
analysis. 
R programming language and software environment version 3.1.3 (R Foundation for 
Statistical Computing, Vienna, A) was used to perform all statistical analyses. All p-values 
were two-sided with p-values <0.05 considered statistically significant.   
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Results 
Between 2008 and 2015, a total of 371 consecutive PCa patients before RP were included. 
The clinical and pathological characteristics, preoperative serum lipid levels and statin use are 
summarized in Table 1. A total of 108 (29.2%) men had extraprostatic disease and 79 (21.4%) 
had high-risk disease (Gleason score ≥8). Furthermore, 25 (6.7%) men were diagnosed with 
lymph node metastasis. Pelvic lymphadenectomy was performed in 277 (74.7%) men. Median 
preoperative serum lipid levels (total cholesterol, LDL cholesterol, HDL cholesterol, 
triglycerides) are also presented in Table 1. LDL cholesterol was non-calculable in five 
patients (1.3%) due to high cholesterol levels (>4.5 mM). These patients were excluded from 
all analyses, which used LDL cholesterol as a variable. A total of 61 (16.4%) men were statin 
users at the time of surgery. A total of 52 patients (14%) were excluded from the analysis of 
time to BCR due to postoperative PSA persistence (n=17) or unavailable follow-up data 
regarding BCR (n=35) after RP. Median follow-up time for the remaining 319 men was 28 
months (range 1-64). BCR occurred in 49 patients (15.4%) after a median time of 18 months 
(2-51). 
Univariable logistic regression analysis (Table 2) revealed a significant association between 
triglycerides (continuous) and high-risk disease (OR: 1.32; 95%-CI: 1.03-1.69; p=0.03). 
However, the association between triglycerides and high-risk disease could not be confirmed 
when triglycerides were used as a dichotomized variable (OR: 1.05; 95%-CI: 0.63-1.75; 
p=0.86). All other serum lipid levels (continuous and dichotomized) did not reveal any 
significant association with pathological tumor characteristics (Table 2). Among all 
pathological parameters, statin use only showed a positive association with PSM (OR: 1.94; 
95%-CI: 1.12-3.39; p=0.02). In an additional univariable logistic regression analysis, 
preoperative serum lipid levels and statin use were not associated with high preoperative PSA 
values (≥10 ng/ml) (Table S1). 
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For prognostic association of serum lipid levels and statin use uni- and multivariable Cox 
regression analyses were performed. Among all preoperative lipid values, only high LDL 
(continuous and 3 mM cut-point) cholesterol values were significantly associated with longer 
recurrence free survival (RFS) compared to low LDL values in univariable analysis 
(continuous: HR: 0.67, 95%-CI: 0.47-0.96, p=0.03; 3 mM cut-point: HR: 0.44, 95%-CI: 0.24-
0.79, p=0.006). Additionally, all clinicopathological study outcomes (stage ≥pT3, Gleason 
score ≥8, pN1 and PSM) were highly associated with a shorter RFS (for all p<0.001) in 
univariable analyses (Table 3). Statin use was not associated with RFS (HR: 1.75, 95%-CI: 
0.91-3.37, p=0.09). 
Regression parameters from multivariable models evaluating the independent prognostic 
utility of LDL cholesterol (continuous and 3 mM cut-point) are presented in Table 4. LDL 
cholesterol remained an independent prognostic factor in a multivariable models adjusting for 
age, PSA, extraprostatic disease, high-risk disease, positive nodal status, PSM and statin use. 
Table S2 shows cut-point testing for LDL cholesterol (1.5 to 5 mM). After correction for 
multiple comparisons, 3.5 mM was another cut-point (besides 3.0 mM) that could predict time 
to BCR (HR: 0.38; 95%-CI: 0.19-0.77; p=0.01; FDR-adjusted p-value: 0.03). Finally, Kaplan-
Meier analysis in regard to BCR for the two LDL cholesterol cut-points (Figure 1: 3.0 mM, 
Figure 2: 3.5 mM) confirmed that the low LDL cholesterol subgroups were significantly 
associated with shorter time to BCR (p=0.005 for both cut-points). 
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Discussion 
Altered lipid metabolism has been acknowledged as a hallmark of many cancers including 
PCa [15,16]. Cancer cells exhibit increased lipid metabolism for energy generation and 
intracellular signaling, both of which are important for maintaining tumor cell survival [17]. 
Thus, there is a biological rationale for the investigation of dyslipidemia and lipid levels in 
cancer patients. Furthermore, epidemiologic studies have suggested that systemic metabolic 
disorders might be involved in PCa development and progression [18]. In this study we 
evaluated the prognostic role of preoperative serum lipid levels after a median follow-up of 28 
months in 371 patients. Low LDL cholesterol remained an independent predictor for shorter 
RFS after RP for localized PCa. Other preoperative serum lipid serum levels (total 
cholesterol, HDL cholesterol and triglycerides) and statin use showed no significant 
association with the clinical course after RP in this cohort. 
The main strength of this work is the prospective comprehensive evaluation of the complete 
preoperative lipid status consisting of the main serum lipid parameters and statin intake before 
RP. Only few studies in the past have evaluated the association of the complete preoperative 
serum lipid status and RFS after curative treatment for localized PCa. Regarding the 
prognostic role of LDL cholesterol conflicting results have been reported [7–10]. 
Two studies did not find any association between preoperative LDL cholesterol and outcome 
after RP for localized PCa. However, only one study [8] is comparable to ours. The cohort of 
the second study by Allot et al. [7] is characterized by almost 40% Gleason 6 cancer patients 
(compared to 13% in our cohort). Moreover, no information about the time point of blood 
sampling before surgery is available for this study. Two further studies reported pretreatment 
high LDL cholesterol levels to be associated with PCa recurrence, which contradicts our 
results [9,10]. Most patients in these two studies were treated with percutaneous radiotherapy 
and are thus not directly comparable to our work. Additionally, both studies have again 
reported a much higher amount of low risk PCa patients (between 44% up to 60% Gleason 6 
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cancer) compared to our study. Finally, only a small subset of the entire cohort could be 
investigated for the complete pretreatment lipid levels (including LDL cholesterol) in one of 
the two studies [9]. In conclusion, different results have been reported regarding LDL 
cholesterol and its association with outcome after treatment of PCa. Heterogeneous cohorts 
with different populations and different therapies limit the comparison between the mentioned 
studies. To the best of our knowledge, our study is the first reporting preoperative low LDL 
cholesterol levels to be associated with PCa recurrence in men with localized PCa undergoing 
RP. 
The role of low serum cholesterol on carcinogenesis is a hot topic in epidemiologic research, 
especially due to the high prevalence of cardiovascular morbidity and the resulting 
prescription of lipid-lowering agents such as statins [19–25]. 
One might explain the results of our investigation by the following hypothesis: Patients with 
preoperatively low LDL cholesterol levels may represent a group with higher and more 
aggressive tumor burden, which has the ability to alter the body´s lipid metabolism leading to 
lower LDL cholesterol values and a higher risk for BCR. The essential question – as asked in 
a comprehensive Mendelian randomization study of Benn et al. [26] – is if the often 
independent association between low serum lipid levels and adverse oncologic outcomes is 
caused by a possible carcinogenic effect of low serum lipid levels or if we see a reverse 
causality, in which a preclinical malignancy alters the serum lipid metabolism. The study, 
which included over 10 000 participants, concludes that low LDL cholesterol is probably 
secondary to preclinical cancer and that a causal relationship between serum lipid values and 
carcinogenesis is unlikely. Gilbert et al. demonstrated an inverse relationship between tumor 
mass of hematological cancers and serum cholesterol [27].Possible cell-biologic explanations 
for the reduction of LDL cholesterol in oncologic patients are the overutilization of serum 
lipids by cancer cells or the secretion of a humoral factor (by cancer cells) which stimulates 
normal cells to utilize LDL cholesterol [28–30]. A recent study has demonstrated that PCa 
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cells require cholesterol for cell growth in vitro, thus it is reasonable to assume that faster 
growing tumors would consume more circulating LDL cholesterol [31]. In summary, the 
adverse role of low LDL cholesterol may be rather interpreted as a cause of cancer and may 
thus not represent a modifiable risk factor in preventing risk of PCa recurrence. As only 
preoperative serum lipid values were available for analysis, the dynamic changes of these 
parameters during the postoperative follow-up period, which might have yielded additional 
interesting results, were not included in this study, but should be included in future study 
protocols. 
Studies from basic and translational research suggest a role for statins in PCa development or 
recurrence by several mechanisms [32]. In our study, statin use was not associated with PCa 
recurrence after RP. Conflicting results have been reported regarding statin use and PCa 
recurrence after curative treatment for localized disease. In line with our work, two relatively 
new meta-analyses that included patients undergoing RP or curative radiation therapy could 
not detect a significant association between statin use and PCa recurrence after RP [33,34]. 
Our study has limitations: Firstly, the relatively short follow-up time, which led to a limited 
number of events. Secondly, only BCR and not PCa specific mortality was available as an 
oncological outcome parameter. BCR is a suboptimal oncological endpoint for PCa due to its 
rather limited ability to predict cancer-specific survival in PCa [35]. However, a shorter RFS 
is a surrogate marker for worse outcome in PCa after curative treatment [36,37]. Thirdly, 
other possible covariates/confounders of serum lipid status such as BMI or smoking status 
were not available for this study. Finally, the duration of preoperative statin intake was not 
controlled. However, the prediction of a shorter RFS by low LDL cholesterol was 
independent from statin intake in multivariable analyses. Our work provides a comprehensive 
blood analysis of all preoperative lipid serum levels in a consecutive series of PCa patients 
undergoing RP. 
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Conclusions 
This is the first study showing the potential prognostic role of low preoperative LDL 
cholesterol levels in a prospective cohort of patients with localized PCa undergoing RP. If 
long-term outcomes confirm our findings, preoperative low LDL cholesterol values might be 
used to categorize patients with localized PCa in a high-risk group for disease recurrence. 
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Figure legends 
 
Figure 1: Kaplan-Meier analysis and the corresponding log-rank test comparing time to 
biochemical recurrence between patients with low and high LDL cholesterol levels (3.0 mM 
cut-point). 
 
Figure 2: Kaplan-Meier analysis and the corresponding log-rank test comparing time to 
biochemical recurrence between patients with low and high LDL cholesterol levels (3.5 mM 
cut-point). 
 
